Measuring time to biochemical failure in the Trog 96.01 trial: when should the clock start ticking?

- Denham, James W., Steigler, Allison, Gleeson, Paul S., D'Este, Catherine, Kumar, Mahesh, Lamb, David S., Joseph, David, Spry, Nigel A., Tai, Keen-Hun, Atkinson, Chris, Turner, Sandra, Greer, Peter B.

Recognizing false biochemical failure calls after radiation with or without neo-adjuvant androgen deprivation for prostate cancer

- Denham, James W., Kumar, Mahesh, Turner, Sandra, Greer, Peter B., D'Este, Catherine, Steigler, Allison, Gleeson, Paul S., Lamb, David S., Joseph, David, Atkinson, Chris, Matthews, John, Tai, Keen-Hun, Spry, Nigel A., Christie, David

Why are pretreatment prostate-specific antigen levels and biochemical recurrence poor predictors of prostate cancer survival?

- Denham, James W., Steigler, Allison, Wilcox, Chantelle, Lamb, David S., Joseph, David, Atkinson, Chris, Tai, Keen-Hun, Spry, Nigel A., Gleeson, Paul S., D'Este, Catherine

Time to biochemical failure and prostate-specific antigen doubling time as surrogates for prostate cancer-specific mortality: evidence from the TROG 96.01 randomised controlled trial

- Denham, James W., Steigler, Allison, Gleeson, Paul S., Greer, Peter B., D'Este, Catherine, Wilcox, Chantelle, Lamb, David S., Joseph, David, Atkinson, Chris, Matthews, John, Tai, Keen-Hun, Spry, Nigel A., Christie, David